Evidence map›Paper›PMID 41898704›Full record

ArticleInternational journal of molecular sciences2026

Targeting G6PD (Glucose-6-Phosphate Dehydrogenase) as a Biomarker of Therapeutic Vulnerability in Renal Cell Carcinoma.

Daniel Pinheiro Ferreira, Ana Carolina Souza Mizael, Julia Victória Bonifácio Cabrieira, Rafaela Viviane Neves Silva, Liliane Silvano Araújo, Crislaine Aparecida Silva, Karen Bento Ribeiro, Adilha Misson Rua Michelleti, Juliana Reis Machado, Régia Caroline Peixoto Lira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel Pinheiro FerreiraClinics Hospital, Universidade Federal do Triângulo Mineiro, Uberaba 38025-180, Brazil.
Ana Carolina Souza MizaelDepartment of Pathology, Genetics and Evolution, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil.ORCID 0009-0003-1399-0592
Julia Victória Bonifácio CabrieiraDepartment of Pathology, Genetics and Evolution, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil.ORCID 0009-0005-9148-6652
Rafaela Viviane Neves SilvaKidney Research Center, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil.
Liliane Silvano AraújoKidney Research Center, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil.
Crislaine Aparecida SilvaKidney Research Center, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil.ORCID 0000-0002-0615-1446
Karen Bento RibeiroClinics Hospital, Universidade Federal do Triângulo Mineiro, Uberaba 38025-180, Brazil.
Adilha Misson Rua MichelletiDepartment of Clinical Surgery, Universidade Federal do Triângulo Mineiro, Uberaba 38025-440, Brazil.
Juliana Reis MachadoDepartment of Pathology, Genetics and Evolution, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil.
Régia Caroline Peixoto LiraDepartment of Pathology, Genetics and Evolution, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil.ORCID 0000-0002-1217-3852

Funding

Centro de Pesquisa em Rim - CePRim, UFTM (CePRim)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-00258-21
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is the most common kidney cancer, with increasing global incidence. Despite advances with VEGF-targeted tyrosine kinase inhibitors (TKIs) and immunotherapies, therapeutic resistance remains frequent, limiting long-term benefits. This highlights the need for potential biomarkers of tumor aggressiveness and therapeutic candidates, such as glucose-6-phosphate dehydrogenase (G6PD), whose altered expression has been associated with several cancers. We evaluated

Indexed as

Biomarkers, TumorCarcinoma, Renal CellGlucosephosphate DehydrogenaseKidney NeoplasmsAnilidesCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMalePyridinesVascular Endothelial Growth Factor AAnilidesBiomarkers, TumorG6PD protein, humanGlucosephosphate DehydrogenasePyridinesVascular Endothelial Growth Factor AG6PDrenal cell carcinomatherapeutic targettumor aggressiveness

Identifiers

PMID41898704
PMCPMC13027040

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.